Q-omics provides the consensus-scored TAAR9 profile across patient tissues and cancer cell-line models. TAAR9 expression is associated with patient survival in 9 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, TAAR9 is differentially expressed in 1, with the highest sampling consensus in KICH. Additionally, TAAR9 RNA expression shows 8,579 significant gene co-expression associations, with the highest sampling consensus in LIHC. Together, these results highlight LUAD, KICH, and LIHC as cancer lineages where TAAR9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TAAR9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TAAR9 survival associations across molecular data types. TAAR9 RNA expression shows survival associations in the most cancer types (9), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TAAR9 RNA expression–survival associations across cancer types. High TAAR9 expression shows unfavorable associations in LUAD, HNSC, BLCA, UCEC and THYM, but favorable associations in KIRC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for TAAR9 RNA expression.
This table summarizes TAAR9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for TAAR9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TAAR9 shows lower tumor expression in KICH. The KICH box plot shows higher TAAR9 RNA expression in normal versus tumor tissue (log2 FC = −0.039, t-test p < 0.001).
This table shows molecular features associated with TAAR9 in patient tissues and cancer cell lines. In patient samples, TAAR9 shows the broadest associations at the RNA and protein expression levels, with LIHC recurring as the lineage with the largest associated feature set. In cancer cell lines, TAAR9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and UPPER_AERODIGESTIVE_TRACT.
